Related Experiment Video

Updated: Jul 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Re: Additional treatment for pT3 prostate cancer: now, later or never

William Reid Pitts

    BJU International
    |June 20, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Retzius-Sparing Robot-Assisted Radical Prostatectomy
    12:10

    Retzius-Sparing Robot-Assisted Radical Prostatectomy

    Published on: May 19, 2022

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Related Experiment Videos

    Last Updated: Jul 4, 2026

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Retzius-Sparing Robot-Assisted Radical Prostatectomy
    12:10

    Retzius-Sparing Robot-Assisted Radical Prostatectomy

    Published on: May 19, 2022

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Diet and risk of bladder cancer: a systematic review of epidemiological evidence.

    BJU international·2026

    Urological issues in masculinising genital surgery: a Delphi consensus study.

    BJU international·2026

    Safety and feasibility of telesurgical robot assisted radical prostatectomy: prospective pilot study.

    BJU international·2026

    Inguinal/pelvic lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT.

    BJU international·2026

    In vitro evaluation of the new holmium:yttrium-aluminium-garnet laser with Magneto technology on behalf of the Progress and Collaboration in Endourology (PACE) group.

    BJU international·2026

    Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.

    BJU international·2026

    Morphology and Beyond - A Rare Case of Metastatic Succinate Dehydrogenase-Deficient Paraganglioma of the Vulva.

    Annals of African medicine·2026

    Occult Breast Carcinoma Presenting with Extensive Bone Involvement in the Absence of an Identifiable Primary Breast Lesion: A Case Report.

    Journal of investigative medicine high impact case reports·2026

    Impact of omitting contralateral systematic biopsy on clinically significant upgrading at radical prostatectomy: a retrospective paired-design study.

    International urology and nephrology·2026

    Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing's syndrome.

    Therapeutic advances in endocrinology and metabolism·2026

    Atypical notochordal cell tumors: an alternative diagnosis when diagnostic criteria are not straightforward : Short title: atypical notochordal cell tumor.

    Virchows Archiv : an international journal of pathology·2026

    Survival Outcomes With Concurrent Systemic Therapy in Patients With a Medical Contraindication to Cisplatin in the Non-Operative Management of Locally Advanced HNSCC, an NCDB Study.

    Head & neck·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us